APLM (Apollomics Inc.) Rasio rega marang prakiraan pendapatan
Apollomics, Inc. (APLM) attracts leading oncologists through large-scale research and generous R&D funding. The expected P/S metric visualizes this intellectual potential, where the value of 6.30 characterizes this level. Monopoly prospects driven by lung cancer patents are complemented by a strategy of avoiding price wars in favor of regulatory approvals, which shapes the current trend on the chart.
APLM (apollomicsinc.com): rincian analitis lan laporan miturut indikator
- rega pasar lan target rega analis:
- indikator valuasi pasar bisnis:
- indikator nilai buku ekuitas:
- data utang lan likuiditas:
Utang marang Ekuitas Apollomics, Inc.|APLM - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Apollomics|APLM - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Apollomics, Inc.|APLM - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan Apollomics|Likuiditas cepet apollomicsinc.com
- data bathi bisnis lan rasio investasi:
APLM - Asil keuangan resik|Bathi mangsa ngarep Apollomics, Inc.|APLM - Nilai perusahaan marang bathi resik|Pangali Forward P/E Apollomics|APLM - Kapitalisasi marang bathi resik kanthi nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Apollomics, Inc.|APLM - Bathi operasional sadurunge amortisasi|Bathi resik saben saham (EPS TTM) Apollomics|APLM - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan apollomicsinc.com|APLM - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep Apollomics, Inc.
- indikator pendapatan dodolan lan penghasilan bisnis:
Analisis kabeh metrik perusahaan:Apollomics Corp APLM
The forward P/S reflects the market valuation of the business relative to expected sales volume, allowing for the determination of the growth premium or the risk of asset overvaluation. By analyzing the forward price-to-sales ratio, an investor can gauge the sensitivity of Apollomics, Inc. (APLM) capitalization to FDA and NMPA decisions, which directly determine the scaling pace of the oncology ecosystem and the influx of new patients.
Analisis perusahaan pesaing
Rasio rega marang prakiraan pendapatan BeiGene ONC|HALO (Halozyme Therapeutics, Inc.) - Rega mangsa ngarep marang pendapatan|RVMD - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Ascentage Pharma Corp|CG Oncology, Inc. (CGON) - Rasio rega marang prakiraan pendapatan|URGN (urogen.com) - Rasio rega marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Bicara Therapeutics|Rasio rega marang prakiraan pendapatan PSNL|Rasio rega marang prakiraan pendapatan Erasca Corp (ERAS)|DCTH - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan Y-mAbs Therapeutics YMAB|AURA - Multiplikator forward rega marang pendapatan|Candel - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Accuray Inc ARAY|SLS: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Actuate Therapeutics Inc|Rasio rega marang prakiraan pendapatan Citius Oncology, Inc.|TuHURA (HURA) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan TARA (Protara Therapeutics, Inc.)|FATE (Fate Therapeutics Inc) - Rega forward marang dodolan|Multiplikator Forward P/S WHWK (Aadi Bioscience)|Rasio kapitalisasi marang dodolan sing dikarepake TScan Therapeutics Inc (TCRX)|CSBR - Rasio rega marang prakiraan pendapatan|XBIT (XBiotech Inc.) - Kapitalisasi marang prakiraan pendapatan|CVM: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan OS Therapies Inc.|Multiplikator forward rega marang pendapatan RADX|Artiva (ARTV) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S ANL|Multiplikator Forward P/S verupharma.com (VERU)|Rasio rega marang prakiraan pendapatan Tempest Therapeutics, Inc. TPST|XLO (Xilio Therapeutics Inc) - Rega mangsa ngarep marang pendapatan|RENB - Rasio rega marang prakiraan pendapatan|MURA: Rasio rega marang prakiraan pendapatan|kairospharma.com (KAPA) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan OnKure Therapeutics|GDTC (CytoMed Therapeutics Ltd) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Curis Corp (CRIS)|Multiplikator Forward P/S THAR|Multiplikator Forward P/S advanbiomed.com (ADVB)|Rasio rega marang prakiraan pendapatan Genprex, Inc. GNPX|CLDI: Kapitalisasi marang prakiraan pendapatan|Sunshine Biopharma, Inc. - Multiplikator Forward P/S|Xenetic Biosciences (XBIO) - Multiplikator forward rega marang pendapatan|SLRX: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Kitov Pharma (PPBT)|Rasio rega marang prakiraan pendapatan American Oncology Network Inc|BGNE: Rega forward marang dodolan|Multiplikator forward rega marang pendapatan CKPT (Checkpoint Therapeutics, Inc.)|ELEV (elevationoncology.com) - Rega forward marang dodolan|Multiplikator Forward P/S ICAD (iCAD)|IKNA - Multiplikator forward rega marang pendapatan|NTBL: Multiplikator forward rega marang pendapatan|VIRX - Multiplikator Forward P/S|MorphoSys (MOR) - Rasio rega marang prakiraan pendapatan|NAYA Biosciences Inc - Rega forward marang dodolan|AAPGV (Ascentage Pharma Group Ltd) - Multiplikator Forward P/S
